Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Alzheimer Disease and Associated Disorders
|
May 27, 2022
E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies
Ishani S Landry, Peter Boyd, Jagadeesh Aluri, et al.
Alzheimer Disease and Associated Disorders
|
June 14, 2022
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial
Ishani S Landry, Jagadeesh Aluri, Edgar Schuck, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 4, 2020
Disposition and Metabolism of [<sup>14</sup>C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites
Takashi Ueno, Tomomi Ishida, Jagadeesh Aluri, et al.
Clinical and Translational Science
|
February 26, 2025
Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Theingi M Thway, Jagadeesh Aluri, Bojan Lalovic, et al.
Journal of Clinical Pharmacology
|
August 20, 2004
Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention
Donna S Cox, Neal S Kleiman, Duane A Boyle, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Natasha Penner, Sumit Rawal, Jagadeesh Aluri, et al.
Journal of Clinical Pharmacology
|
May 14, 2026
A Phase 1 Oral Mass Balance and Combined Intravenous [<sup>14</sup>C] Microtracer Study to Characterize the Absorption, Metabolism, Excretion, and Pharmacokinetics of Antitumor Drug E7386 in Humans
Shriram M Pathak, Nozomi Hayata, Takashi Ueno, et al.
Clinical Pharmacology in Drug Development
|
January 17, 2021
Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant
Ishani Landry, Jagadeesh Aluri, Kenya Nakai, et al.
Journal of Clinical Pharmacology
|
June 25, 2016
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant
Patricia J Murphy, Sanae Yasuda, Kenya Nakai, et al.
Alzheimer Disease and Associated Disorders
|
July 17, 2025
An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects
Sumit Rawal, Kristin R Wildsmith, Jagadeesh Aluri, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Alzheimer Disease and Associated Disorders
|
May 27, 2022
E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies
Ishani S Landry, Peter Boyd, Jagadeesh Aluri, et al.
Alzheimer Disease and Associated Disorders
|
June 14, 2022
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial
Ishani S Landry, Jagadeesh Aluri, Edgar Schuck, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 4, 2020
Disposition and Metabolism of [<sup>14</sup>C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites
Takashi Ueno, Tomomi Ishida, Jagadeesh Aluri, et al.
Clinical and Translational Science
|
February 26, 2025
Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Theingi M Thway, Jagadeesh Aluri, Bojan Lalovic, et al.
Journal of Clinical Pharmacology
|
August 20, 2004
Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention
Donna S Cox, Neal S Kleiman, Duane A Boyle, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Natasha Penner, Sumit Rawal, Jagadeesh Aluri, et al.
Journal of Clinical Pharmacology
|
May 14, 2026
A Phase 1 Oral Mass Balance and Combined Intravenous [<sup>14</sup>C] Microtracer Study to Characterize the Absorption, Metabolism, Excretion, and Pharmacokinetics of Antitumor Drug E7386 in Humans
Shriram M Pathak, Nozomi Hayata, Takashi Ueno, et al.
Clinical Pharmacology in Drug Development
|
January 17, 2021
Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant
Ishani Landry, Jagadeesh Aluri, Kenya Nakai, et al.
Journal of Clinical Pharmacology
|
June 25, 2016
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant
Patricia J Murphy, Sanae Yasuda, Kenya Nakai, et al.
Alzheimer Disease and Associated Disorders
|
July 17, 2025
An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects
Sumit Rawal, Kristin R Wildsmith, Jagadeesh Aluri, et al.
Page
of 4